Vaccinex and its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37th Annual Meeting of Society for Immunotherapy of Cancer

November 10, 2022

https://www.globenewswire.com/news-release/2022/11/10/2553310/34858/en/Vaccinex-and-its-Collaborators-Present-Two-Abstracts-Related-to-Pepinemab-Combination-Immunotherapy-Trials-at-37th-Annual-Meeting-of-Society-for-Immunotherapy-of-Cancer.html

ROCHESTER, N.Y., Nov. 10, 2022 (GLOBE NEWSWIRE) — Vaccinex, Inc. (Nasdaq:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D), and its collaborators at Emory University and the Moffitt Cancer Center today announced that two abstracts, including an oral presentation and a poster related to investigator-sponsored trials for pepinemab combinations, are being presented at The Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting.

Read more at globenewswire.com

Related news for (VCNX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.